Glyscend Therapeutics completes $20.5 million round A financing for the development of new oral polymer therapies for T2D metabolic diseases

Read: Glyscend Glyscend Completes $20.5 Million FinancingJune 12, 2020, Arterial Network (public number: vcbeat) was informed that Glyscend announced on June 11, local time, the completion of the $20.5 million round of a financing, the current round of investment led by Sant Ventures, Brandon Capital Partners to completeit is understood that Glyscend has completed a $500,000 stake since its inception in 2014, following government grants and round A financing in 2016 and 2020, respectively(finance information from crunchbase)this round of financing will be used for research and development of new oral polymer therapies for patients with T2D and other metabolic diseasesAshish Nimgaonkar, President and CEO ofGlyscend, said: "The technology we are developing is inspired by the excellent efficacy of gastric bypass surgery in correcting T2D-related metabolic abnormalitiesOur goal is to develop an oral drug that works in gastrointestinal prosthesis, taking advantage of the benefits of gastric bypass surgery while significantly reducing potential risks and complicationsHe added: "To simulate the benefits of these invasive ways of using pills, Glyscend's research team drew on the experience of Thomas Jozefiak, a pharmaceutical polymer chemist who pioneered the absorption-free compound when working at GelTex Pharmaceuticals (later renamed Genzyme), which later became a heavyweight drug used by Sanofi for the treatment of chronic kidney disease." Bob Soh, investment manager at brandon Capital Partners,, said: "I've been privileged over the years to see the Glyscend team develop and validate its compoundsClinical researchers in Australia have long endorsed this approach and are looking forward to the first human trials starting next year"
about Glyscend TherapeuticsGlyscend, Inc., a venture-based biopharmaceutical company that is working on the development of new oral drugs that can act on targets in the gastrointestinal tract and treat a variety of metabolic diseases, including T2DGlyscend's polymer technology platform draws on research by Johns Hopkins University that certain types of bariatric surgery have mechanisms that significantly improve glucose and metabolic regulationThey found that specially designed polymers can simulate such postoperative mechanisms after they are taken orally into the body by miceGlyscend's technology originated with research initiated by the Center for Bioengineering Innovation and Design (CBID) at Johns Hopkins University and was licensed by the university The project has received funding and recognition from Maryland Innovation Initiative, the National Science Foundation, Johnson and Johnson Research and Development 2016 World Without Disease Quick Fire Challenge Brandon Capital Partners
Brandon Capital Partners is a fund management company that aims to deliver high-quality returns to Australia's top pension funds by investing in innovative life sciences companies The company works with entrepreneurs to build business partnerships that create value for entrepreneurs, their teams and their investors The company was founded in 2006 and is headquartered in Melbourne, Australia about sant's ventures
Sant Ventures is a life sciences venture capital firm that specializes in the development of innovative new medical technologies or early healthcare models The company was founded in 2006 and manages two funds with total assets of $281 million